Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Non-Current Deffered Revenue (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $431000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Non-Current Deffered Revenue fell 63.1% to $431000.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $431000.0, a 63.1% decrease, with the full-year FY2023 number at $433000.0, down 61.61% from a year prior.
  • Non-Current Deffered Revenue was $431000.0 for Q1 2024 at Werewolf Therapeutics, roughly flat from $433000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.3 million in Q1 2021 to a low of $11000.0 in Q3 2021.
  • A 4-year average of $673545.5 and a median of $600000.0 in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 4544.44% in 2022, then crashed 63.1% in 2024.
  • Werewolf Therapeutics' Non-Current Deffered Revenue stood at $11000.0 in 2021, then soared by 10154.55% to $1.1 million in 2022, then tumbled by 61.61% to $433000.0 in 2023, then fell by 0.46% to $431000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Non-Current Deffered Revenue are $431000.0 (Q1 2024), $433000.0 (Q4 2023), and $600000.0 (Q3 2023).